Estriol Test · Blood

If you have ever wondered whether your body's estrogen picture is more complex than a single estradiol number suggests, estriol is one of the missing pieces. It is the weakest of the three main estrogens your body makes, and outside of pregnancy it circulates at very low levels. But those low levels still carry information, especially for women navigating menopause, monitoring hormone therapy, or trying to understand the full scope of their estrogen metabolism.

Estriol (E3) does not yet have the standardized clinical cutpoints or large outcome studies that markers like estradiol or cholesterol enjoy. That means a single reading will not hand you a clear "normal" or "abnormal" verdict. What it can do is add texture to your hormonal profile, particularly when paired with estradiol and estrone, and give you a baseline to track over time as the science around this marker continues to mature.

What Estriol Is and Where It Comes From

Your body produces three principal estrogens: estradiol (E2), estrone (E1), and estriol (E3). Estradiol is the strongest and most abundant in reproductive-age women. Estrone takes over after menopause. Estriol is the weakest of the three, binding estrogen receptors with far less strength than estradiol. In non-pregnant adults, estriol circulates at very low concentrations.

During pregnancy, estriol production shifts dramatically. The developing baby's adrenal glands and liver produce chemical precursors that travel to the placenta, where enzymes convert them into estriol. This collaboration between the fetus and placenta (sometimes called the fetoplacental unit) causes maternal estriol to rise progressively throughout pregnancy, reaching levels far higher than either estradiol or estrone.

Estriol in Pregnancy

Because estriol production during pregnancy depends on a healthy fetus, a functioning placenta, and adequate blood flow between them, maternal estriol levels serve as a window into how well that system is working. Abnormally low estriol in the second trimester (below 0.5 MoM, a unit that adjusts for how far along the pregnancy is) has been linked to higher risk of pregnancy-related high blood pressure (preeclampsia), miscarriage, restricted fetal growth, and fetal death. These associations likely reflect underlying placental dysfunction.

In women with severe preeclampsia, estriol and certain related molecules called estriol epimers (chemically similar variants of estriol that differ at a single point in their structure) are significantly lower than in women with normal blood pressure during pregnancy. This suggests that the placenta's ability to produce estriol and its protective anti-inflammatory variants is compromised.

On the other end, an early or exaggerated estriol surge in saliva (at or above 2.3 ng/mL) has been associated with an increased risk of preterm labor, with one study reporting that it correctly identified about 71% of women who delivered early (sensitivity) and correctly identified about 77% of women who did not (specificity). A normal, gradual rise in estriol typically occurs about three weeks before labor begins, whether at term or preterm.

Estriol Outside of Pregnancy

In non-pregnant adults, estriol levels are very low. A large study of 1,838 healthy participants using LC-MS/MS (a highly sensitive lab technique that directly measures hormone molecules) confirmed that estriol is detectable but did not establish formal reference ranges for it outside of pregnancy. The study's detection threshold for estriol was extremely low, and clinical reference intervals were published only for estradiol and estrone.

This means that for non-pregnant individuals, estriol occupies a different clinical space than estradiol. It is not a marker your doctor typically uses to diagnose a condition or guide treatment. Instead, it can serve as part of a broader estrogen metabolism panel, especially when all three estrogens (E1, E2, E3) are measured together. That fractionated view can reveal patterns in how your body processes estrogens, which some practitioners use when managing hormone therapy or evaluating estrogen-related symptoms.

Therapeutic Uses of Estriol

While this article focuses on estriol as a measured biomarker, understanding how estriol is used as a treatment helps explain why some people track it. Low-dose vaginal estriol (particularly ultra-low 0.005% gel formulations delivering about 50 micrograms) has been studied in randomized trials for vaginal dryness and tissue thinning after menopause. In a trial of 167 postmenopausal women, this formulation improved vaginal tissue health, pH, and dryness symptoms over 12 weeks compared to placebo, with good safety. A separate trial of 110 women found it also improved sexual function and quality of life.

In a randomized trial of 116 postmenopausal women with painful intercourse, 1 mg vaginal estriol improved pain and sexual function without raising serum estriol levels, suggesting the effect stays local. For postmenopausal women with recurrent urinary tract infections (UTIs), a controlled trial of 93 women found that intravaginal estriol cream reduced UTI episodes from 5.9 per patient-year with placebo to 0.5 per patient-year with treatment, while restoring healthy vaginal bacteria and lowering pH.

For women with breast cancer taking aromatase inhibitors (drugs that block estrogen production), safety is a particular concern. A phase II trial of 61 such women found that ultra-low-dose estriol vaginal gel caused only brief, very small estriol increases in blood, with estradiol and estrone remaining undetectable, supporting short-term safety for treating vaginal symptoms in this population.

Estriol and the Immune System

Pregnancy often improves autoimmune conditions like multiple sclerosis (MS), and researchers have studied whether estriol might be partly responsible. In a pilot study, oral estriol at pregnancy-level doses (8 mg per day) reduced inflammatory brain lesions visible on MRI in women with relapsing-remitting MS. When the drug was stopped, lesions returned; when it was restarted, they improved again. Blood tests showed a shift in immune signaling: levels of anti-inflammatory molecules (IL-5 and IL-10) rose while a pro-inflammatory molecule (TNF-alpha, a protein that drives inflammation) fell.

A larger phase 2 randomized trial of 164 women found that estriol combined with glatiramer acetate (a standard MS medication) reduced the annual relapse rate compared to glatiramer alone (adjusted rate ratio approximately 0.63, p=0.077). The study had pre-set a significance threshold of p=0.10 given its exploratory design, and the result met that threshold, though it would not meet the more conventional p<0.05 standard. The treatment was generally well tolerated. These findings remain investigational and have not led to approved MS treatments, but they illustrate estriol's broader biological activity beyond simple estrogen signaling.

Reference Ranges

This is where honesty matters more than precision. No major clinical guideline or large population study has established standard reference ranges for serum estriol in non-pregnant adults. The best available analytical data comes from an LC-MS/MS study of 1,838 healthy individuals aged 3 months to 61 years, which validated the assay for estriol but published formal reference intervals only for estradiol and estrone.

For pregnancy, unconjugated estriol is typically reported in multiples of the median (MoM), which adjusts for gestational age. Values below 0.5 MoM in the second trimester flag increased risk for pregnancy complications. Your lab will report pregnancy-specific ranges if you are pregnant.

For non-pregnant individuals, your lab may report a reference range based on its own assay, but these are not standardized across laboratories. Different assay methods can produce different numbers from the same sample. This makes it especially important to compare results within the same lab over time rather than against a universal target.

When Results Can Be Misleading

Because estriol circulates at very low levels outside pregnancy, even small measurement variations can look like large percentage changes. The assay method matters: immunoassays (antibody-based tests) may be less accurate at these low concentrations than LC-MS/MS, which directly measures the molecule. If your result seems surprisingly high or low, ask your lab which method was used.

• Kidney function: Estriol is cleared through the kidneys. Impaired kidney function could slow clearance and raise circulating levels without any change in how much your body is producing.
• Acute illness or inflammation: Disease states can shift hormone levels broadly. A reading taken during or shortly after an illness may not reflect your baseline.
• Vaginal estriol therapy: If you are using vaginal estriol cream or gel, even ultra-low doses can cause brief, small increases in blood estriol levels. Time your blood draw to avoid the window immediately after application.
• Specimen handling: Like most hormones, estriol can be affected by how the blood sample is processed and stored. Breakdown of red blood cells in the collection tube or delayed processing may alter results.

Tracking Your Trend

A single estriol reading in a non-pregnant person has limited standalone value. The field does not yet have precise answers to the question "how much does my estriol need to change before that change is real?" because the normal variation in repeated measurements and the minimum meaningful change have not been formally established for estriol. This uncertainty makes serial tracking even more important than for well-characterized markers.

If you are ordering this test as part of a fractionated estrogen panel to understand your hormone metabolism, get a baseline, then retest in 3 to 6 months under similar conditions (same lab, same time of day, same point in your menstrual cycle if applicable). Over time, your own personal trend will be more informative than any single number compared to a population average. If you are making a change, like starting or adjusting hormone therapy, retest after about 3 months to see whether the intervention is reflected in your results.

What to Do With Your Result

If your estriol result arrives and you are not pregnant, the first step is context. Look at it alongside estradiol and estrone if you ordered a fractionated panel. The ratio and pattern across all three estrogens tells a more complete story than any single number. A very low estriol alongside low estradiol in a postmenopausal woman is expected. An unexpectedly high estriol in someone not using estriol therapy or not pregnant warrants a repeat test and possibly further investigation.

If you are pregnant and your unconjugated estriol comes back low (below 0.5 MoM), your provider will typically recommend additional monitoring, which may include ultrasound assessment of fetal growth and placental blood flow. A single low reading is not a diagnosis; it is a signal that closer surveillance is warranted.

Because estriol lacks the clinical infrastructure of more established markers (no guideline-based cutpoints, no outcome-based risk tiers), an endocrinologist or reproductive hormone specialist is the right person to help you interpret results that concern you. This test is best understood as one piece of a larger hormonal picture, not as a standalone decision-making tool.